Scope and Claims Analysis for US Drug Patent 10,945,950 (RPL554 Inhalation Suspension)
US Patent 10,945,950 claims a tightly defined liquid pharmaceutical suspension of RPL554 for inhalation delivery, constrained by (i) buffer presence and phosphate concentration, (ii) particle size distribution (Dv50), (iii) RPL554 concentration, and (iv) optional formulation components (surfactants, tonicity adjusters) and delivery devices (nebulizers). The claim set is structured as a baseline composition claim (claim 1) with narrower dependent claims that remove phosphate/buffer, tighten particle size, and add formulation/device features.
What does claim 1 actually cover? (Core composition boundary)
Claim 1 is the only independent claim you provided; it sets the infringement “gate” for the entire patent family around inhalable RPL554 suspensions.
Claim 1 limitations (all must be met)
A liquid pharmaceutical composition suitable for inhalation comprising:
-
Drug identity
- RPL554: 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable salt.
-
Dosage form
- A suspension of RPL554 particles in a diluent (not a solution).
-
Buffer requirement
- Includes a phosphate buffer at < about 5 mg/mL.
-
Particle size distribution
- Dv50 (median particle size by volume) is 0.2 µm to 5 µm.
-
Drug concentration
- RPL554 concentration in liquid composition is 0.1 mg/mL to 6 mg/mL.
-
Administration route
- Composition is suitable for administration by inhalation.
Operational “scope” statement
Practically, claim 1 covers inhalable nebulizable-like suspensions where the drug is dispersed as particles with Dv50 between 0.2 and 5 µm, at 0.1 to 6 mg/mL, in a diluent that includes phosphate buffer below 5 mg/mL.
How narrow are dependent claims relative to claim 1? (Net tightening)
H2: Which claims cut phosphate/buffer out entirely?**
- Claim 2: composition “according to claim 1” does not comprise a phosphate buffer.
- Claim 3: composition “according to claim 2” does not comprise a buffer.
Scope impact: These dependent claims create alternative embodiments with no phosphate and then no buffer at all, while still remaining “according to claim 1” in the provided text. If the “according to claim 1” requirement is construed as inheriting all claim 1 limitations, the claim dependency would be internally strained because claim 1 requires phosphate buffer at <5 mg/mL, while claim 2 says no phosphate buffer. Claim drafting in real dockets typically resolves this via legal construction of dependency (or through alternative embodiments in the spec). Based strictly on the claim language provided, these dependent claims expand practical coverage to formulations with no phosphate and no buffer, assuming the buffer limitation is overridden in the dependency chain.
H2: Which claims tighten particle size (Dv50)?**
- Claim 4: Dv50 0.7 µm to 2.5 µm.
Scope impact: This is a substantial tightening within claim 1’s 0.2 to 5 µm band. Designs targeting the extremes (0.2 to 0.7 µm or 2.5 to 5 µm) can fall outside claim 4 while remaining within claim 1, depending on how infringement is evaluated claim-by-claim.
H2: Which claims add surfactants, and which ones?**
- Claim 5: further comprises one or more surfactants.
- Claim 6: surfactants are one or more non-ionic surfactants.
- Claim 7: surfactants selected from:
- polyoxyethylene glycol sorbitan alkyl esters
- sorbitan alkyl esters
Scope impact: Surfactant presence is optional at the dependent level (claim 1 does not require it). If surfactants are included, the claims restrict them to non-ionic and specifically to the listed chemical classes. Formulations using ionic surfactants or different non-ionic classes are positioned to avoid dependent claims 5-7, while still potentially remaining within claim 1 if surfactant is not a required element of claim 1.
H2: Which claims require tonicity control, and with what?**
- Claim 8: further comprises a tonicity adjuster.
- Claim 9: tonicity adjuster is sodium chloride.
Scope impact: These dependent claims are narrow. If a competitor uses a tonicity adjuster other than sodium chloride (e.g., mannitol or glycerol) the dependent claims 8-9 can be avoided, while claim 1 may still be relevant.
H2: Which claims specify diluent and administration equipment?**
- Claim 10: diluent is water.
- Claim 11: composition is suitable for administration by nebulizer.
- Claim 12: nebulizer comprising the composition of claim 1.
Scope impact: These are device and diluent refinements. Water-only diluents and nebulizer use are common in inhalation suspension products; they can be easy to meet and therefore do not necessarily narrow much in practice unless competitors use non-water diluents or non-nebulizer administration.
What is the effective infringement “matrix”? (Claim-by-claim boundary tests)
Below is a structured view of the boundaries you provided.
| Claim |
Must contain |
Buffer constraint |
Particle size |
Drug concentration |
Other required features |
| 1 (independent) |
RPL554 (or salt) suspension for inhalation |
Phosphate buffer < 5 mg/mL |
Dv50 0.2 to 5 µm |
0.1 to 6 mg/mL |
inhalation-suitable; diluent + suspension |
| 2 (dep.) |
Inherits claim 1 |
No phosphate buffer |
inherits claim 1 |
inherits claim 1 |
none stated |
| 3 (dep.) |
Inherits claim 2 |
No buffer |
inherits claim 1 |
inherits claim 1 |
none stated |
| 4 (dep.) |
Inherits claim 1 |
inherits claim 1 |
Dv50 0.7 to 2.5 µm |
inherits claim 1 |
none stated |
| 5 (dep.) |
Inherits claim 1 |
inherits claim 1 |
inherits claim 1 |
inherits claim 1 |
surfactant(s) present |
| 6 (dep.) |
Inherits claim 5 |
inherits claim 1 |
inherits claim 1 |
inherits claim 1 |
non-ionic surfactants |
| 7 (dep.) |
Inherits claim 6 |
inherits claim 1 |
inherits claim 1 |
inherits claim 1 |
specific surfactant classes |
| 8 (dep.) |
Inherits claim 1 |
inherits claim 1 |
inherits claim 1 |
inherits claim 1 |
tonicity adjuster present |
| 9 (dep.) |
Inherits claim 8 |
inherits claim 1 |
inherits claim 1 |
inherits claim 1 |
NaCl tonicity adjuster |
| 10 (dep.) |
Inherits claim 1 |
inherits claim 1 |
inherits claim 1 |
inherits claim 1 |
diluent is water |
| 11 (dep.) |
Inherits claim 1 |
inherits claim 1 |
inherits claim 1 |
inherits claim 1 |
nebulizer administration suitability |
| 12 (dep.) |
Inherits claim 1 |
inherits claim 1 |
inherits claim 1 |
inherits claim 1 |
nebulizer comprising composition |
What does this imply for designing around? (Practical scope levers)
Using only the claim limits in your prompt, the primary design-around levers are:
-
Particle size (Dv50)
- If a formulation is engineered to keep Dv50 < 0.2 µm or Dv50 > 5 µm, it avoids claim 1.
- If it stays within claim 1 but you want to avoid claim 4, target Dv50 outside 0.7 to 2.5 µm.
-
Drug concentration
- Avoiding claim 1 requires staying outside 0.1 to 6 mg/mL.
-
Buffer condition
- Claim 1, as provided, is anchored to phosphate buffer < 5 mg/mL. Avoidance can be pursued by removing phosphate buffer and/or removing buffer entirely, though claims 2-3 complicate this because they recite the “no phosphate” and “no buffer” embodiments as dependent claims.
-
Surfactant selection
- To avoid claims 5-7 while remaining within claim 1, use no surfactant or use a surfactant category not captured by the specified non-ionic and listed chemical classes.
-
Tonicity adjuster
- To avoid claims 8-9 while remaining within claim 1, use a tonicity adjuster other than sodium chloride.
-
Diluent
- To avoid claim 10, use a non-water diluent (if commercially and biologically viable).
-
Device/administration
- To avoid claims 11-12 (device-level), deliver without a nebulizer architecture. Inhalation via other devices may reduce exposure to those dependent claims, while leaving claim 1 still potentially applicable if “suitable for administration by inhalation” remains met.
Scope vs. typical inhalation suspension formulations (where claims are likely to read broadly)
Claim 1 does not constrain:
- the exact diluent composition beyond being a “diluent”
- the exact surfactant or tonicity adjuster identity
- the delivery apparatus beyond inhalation suitability
That makes claim 1 the most broadly relevant threat vector for RPL554 inhalation suspensions, since many plausible formulations land inside:
- Dv50 for suspensions (frequently in sub-5 µm ranges)
- RPL554 concentration ranges (often within tens of mg/mL or lower; this claim caps at 6 mg/mL)
- buffer presence (phosphate is common), including at low concentrations
Patent landscape assessment (based on provided claim text only)
A full landscape requires bibliographic data (assignee, filing dates, priority, continuation chain, and related family members). Your prompt includes only the US patent claim text, not the patent’s family, citations, or prosecution history. Under that constraint, the only defensible “landscape” work product is scope mapping against likely competitor formulation dimensions.
H2: Where will competitors most likely concentrate to avoid claim 1?**
Based on claim 1’s numeric windows, competitors will focus on one or more of:
- Dv50 shift outside 0.2 to 5 µm
- RPL554 concentration outside 0.1 to 6 mg/mL
- buffer strategy (phosphate removal or buffer removal) though claims 2-3 suggest the patent also contemplates buffer-free versions
H2: Where do dependent claims create additional carve-outs?**
Dependent claims offer more exit ramps if claim 1 is met but dependents are not:
- Dv50 tightening for claim 4 (0.7 to 2.5 µm)
- surfactant class for claims 5-7
- tonicity adjuster identity for claims 8-9
- water diluent for claim 10
- nebulizer framing for claims 11-12
Key Takeaways
- US 10,945,950 claim 1 is the central independent claim and is governed by three numeric constraints: phosphate buffer < 5 mg/mL, RPL554 Dv50 0.2 to 5 µm, and RPL554 concentration 0.1 to 6 mg/mL, in a liquid inhalation suspension.
- Dependent claims tighten scope mainly through particle-size narrowing (Dv50 0.7 to 2.5 µm) and through optional but specific formulation components: non-ionic surfactants (PEG sorbitan alkyl esters and sorbitan alkyl esters) and NaCl as tonicity adjuster.
- The main design-around levers are Dv50, drug concentration, and (at dependent levels) surfactant identity, tonicity adjuster identity, diluent identity, and nebulizer-only framing.
- A comprehensive “patent landscape” across continuations, family members, and cited art cannot be completed from the claim text alone; the actionable competitive map is therefore limited to claim-parameter landability against the numeric windows.
FAQs
1. What is the single most important limitation for infringement risk?
The most important limitation is claim 1’s Dv50 window (0.2 to 5 µm) combined with RPL554 concentration (0.1 to 6 mg/mL) and the phosphate buffer < 5 mg/mL condition.
2. Can a formulation with Dv50 outside 0.2 to 5 µm still infringe?
It would avoid claim 1 on the provided terms because Dv50 is a required parameter of the independent claim. Dependent claim 4 also requires Dv50 inside 0.7 to 2.5 µm.
3. Do surfactants matter for the independent claim?
No. Surfactants are optional and appear only in dependent claims 5 to 7. Claim 1 does not require surfactants.
4. Is sodium chloride required?
No. Sodium chloride is required only in dependent claim 9 as the tonicity adjuster.
5. Does the patent cover a nebulizer as a product?
Yes. Claim 12 covers a nebulizer comprising the composition of claim 1, and claim 11 requires nebulizer suitability for administration.
References
[1] US Patent 10,945,950, “Liquid pharmaceutical composition comprising RPL554 for inhalation,” claims 1-12 (text provided in prompt).
